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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is
a lethal diffuse fibrosing lung disease
with a 5-year mortality rate greater than
50%, which exceeds many types of can-
cers (1–3). IPF corresponds histopatho-
logically to “usual interstitial pneumo-
nia” (UIP) and comprises a pattern of
fibrosis with interstitial fibroblast prolif-
eration, alveolar destruction and exces-
sive extracellular matrix (ECM) synthesis
and accumulation (4). Studies exploring
the mechanisms that are crucially in-
volved in the development of IPF identi-
fied several possible targets for therapeu-
tic interventions. Among those,
protease-activated receptors (PARs) are
key candidates, as these receptors medi-
ate the cellular effects of coagulation fac-
tors and play central roles in influencing
inflammatory and fibrotic responses
(5–7).
PARs are seven-transmembrane 
G protein–coupled receptors which are
activated by proteolytic cleavage by ser-
ine proteases (8). PAR-2 is one of four
members of the PAR family that is widely
expressed in many different cell types
such as (among others) fibroblasts and
epithelial cells (9). Proteases such as
trypsin, factor (F)VIIa, FXa, mast cell
tryptase or matriptase cleave the 
N-terminal extracellular domain of 
PAR-2, thereby revealing a novel tethered
ligand that binds to PAR-2 and activates
its transmembrane signaling to intracellu-
lar G proteins (10–12). Importantly, acti-
vated PAR-2 mediates a number of
pathophysiological pathways involved in
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acute/chronic inflammatory and fibrotic
diseases of the joints, skin, brain, lung and
gastrointestinal tract (10,12–15).With re-
spect to lung injury and pulmonary fibro-
sis, there is increasing evidence that PAR-2
is a critical contributor in the pathogenesis
of IPF. Increased PAR-2 expression has
been detected in the lungs of patients with
IPF, and a recent study proposed that the
PAR-2/tissue factor (TF)/FVIIa axis may
contribute to the development and/or
progression of IPF (16). This study pro-
vided in vitro evidence that FVIIa exerts
profibrotic effects in human fibroblasts by
specifically activating PAR-2. In line with
this finding, the prototypical PAR-2 ago-
nist tryptase stimulates the growth of
human lung fibroblasts and potentiates
extracellular matrix production in a 
PAR-2–dependent manner (17). More-
over, PAR-2 expression significantly cor-
relates with the extent of honeycombing
(18), and PAR-2 activation has been
shown to be highly relevant to the pro-
gression of pulmonary fibrosis in experi-
mental animal models of bleomycin-in-
duced injury. Indeed, genetic ablation of
PAR-2 in mice affords protection from
pulmonary fibrosis, as evident from a re-
duction in the extent and severity of fi-
brotic lesions and diminished collagen
expression (19). In addition, treatment of
pulmonary fibrosis–bearing rats with di-
allylsulfide or daidzein results in amelio-
ration of collagen production through
the involvement of PAR-2 (20,21).
Notwithstanding the overwhelming
amount of data supporting an important
role of PAR-2 in pulmonary fibrosis,
some controversy has also emerged over
the topic. Indeed, using a similar model
of bleomycin-induced pulmonary fibro-
sis as in the study mentioned above,
edema and hydroxyproline levels were
not different between wild-type and
PAR-2–deficient mice in a study by Su
and colleagues (22). Also, a recent study
showed that protein and mRNA expres-
sion levels of PAR-2 in IPF patients were
not different from those of controls (23),
and it has been claimed that it is doubtful
whether blocking PAR-2 would serve as
an effective treatment strategy for IPF
(24). It is thus fair to state that, despite in-
triguing data supporting a role for PAR-2
in pulmonary fibrosis, its potential clini-
cal relevance remains controversial. In
the present study, we addressed the con-
troversy by first assessing whether PAR-2
deficiency limits bleomycin-induced pul-
monary fibrosis or merely delays disease
progression. We reaffirmed the impor-
tance of PAR-2 and subsequently evalu-
ated the efficacy of pharmacological PAR-
2 inhibition in pulmonary fibrosis.
MATERIALS AND METHODS
Cells and Reagents
Mouse embryonic NIH/3T3 fibroblasts
(American Type Culture Collection;
ATCC CRL-1658) and primary human
lung fibroblasts (derived from pulmonary
control and IPF patient explants as de-
scribed in [25]; provided by INSERM
U1152) were cultured in Dulbecco modi-
fied Eagle medium (DMEM) supple-
mented with 10% fetal calf serum (FCS).
Cells were grown at 37°C in an atmos-
phere of 5% CO2. Unless indicated other-
wise, cells were washed twice with PBS
and serum starved for 4 h before stimula-
tion. Human platelets were donated by a
healthy volunteer and isolated as de-
scribed before (26). Thrombin and trypsin
were from Sigma-Aldrich, whereas 
P2pal-18S (PAR-2 inhibitor [27]; palmitate-
RSSAMDENSEKKRKSAIK-NH2) was
from GL Biochem Ltd.
Calcium Assay
Calcium signaling responses were ana-
lyzed using the Fluo-4 Direct™ Calcium
Assay Kit (Invitrogen) following the
manufacturer’s instructions. Cells were
preincubated with or without 10 μmol/L
P2pal-18S and then challenged with
PAR-1 agonist. Ca2+ flux was monitored
for the indicated time points on a Bio-Tek
HT Multi-Detection Microplate Reader
(Winooski).
Western Blot
Western blots were performed essen-
tially as described before (19). In brief,
cells were lysed in Laemmli lysis buffer
and the lysates were incubated for 5 min
at 95°C. Afterward, protein samples were
separated by 10% SDS gel electrophoresis
and transferred to a PVDF membrane
(Millipore). Membranes were blocked for
1 h in 4% milk in TBST and incubated
overnight with monoclonal antibodies
against α-smooth muscle actin (α-SMA),
glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) or collagen (all Santa Cruz
Biotechnology, Inc.) at 4°C. All secondary
antibodies were horseradish peroxidase
(HRP)- conjugated from DakoCytomation
and diluted according to the manufac-
turer’s instructions. Blots were imaged
using Lumilight plus ECL substrate from
Roche on an ImageQuant LAS 4000 bio-
molecular imager from GE Healthcare.
For quantification, densitometry was
performed using ImageJ.
Animal Model of Pulmonary Fibrosis
Wild-type C57Bl/6 mice were purchased
from Charles River. PAR-2–deficient 
(PAR-2–/–) C57Bl/6 mice were originally
provided by Jackson Laboratories and
bred at the animal care facility of the Aca-
demic Medical Center. All procedures
were performed on 10-wk-old mice in ac-
cordance with the Institutional Standards
for Humane Care and Use of Laboratory
Animals of the Academic Medical Center.
Experiments were approved by the Ani-
mal Care and Use Committee of the Aca-
demic Medical Center. Bleomycin (Sigma-
Aldrich) was administered by intranasal
instillation (1 mg/kg body weight in 45 μL
saline) under anesthesia. In the PAR-2
pepducin dose- finding experiment, ani-
mals were intranasally instilled with 2.5
or 10 mg/kg P2pal-18S half an hour be-
fore bleomycin administration and subse-
quently once daily until the end of the ex-
periment. In the delayed treatment
experiment, mice were treated once daily
with 2.5 mg/kg pepducin starting 1, 3 or
7 d after bleomycin instillation. In both
experiments, 6% DMSO in saline was ad-
ministered as a solvent control. Unless
stated otherwise, mice were killed 14 d
after bleomycin instillation, after which
one lung was taken for histological analy-
sis and one was homogenized.
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Bronchoalveolar Lavage
At 14 d after bleomycin instillation, 
the lungs were lavaged three times with
0.3 mL of saline by a 22-gauge Abbocath-
Tcatheter into the trachea via a midline
incision before animals were killed. The
bronchoalveolar lavage fluid (BALF) was
centrifuged, and the supernatant was
frozen at –70°C until use.
TGF-β ELISA
Transforming growth factor β-1 
(TGF-β1) was measured with the Mouse
TGF-β 1 DuoSet kit (R&D systems) per
the manufacturer’s instructions.
Hydroxyproline Assay
Hydroxyproline analysis was performed
by the hydroxyproline assay kit per the
manufacturer’s instructions (Sigma-
Aldrich) and as described before (28).
Histological Analysis
Histological examination was per-
formed essentially as described before
(19). Briefly, the excised lung was fixed
in formalin and embedded in paraffin,
and then 4-μm–thick slides were subse-
quently deparaffinized, rehydrated and
washed in deionized water. Slides were
stained with hematoxylin and eosin
(H&E) according to routine procedures.
In H&E staining, the severity of fibrosis
was assessed according to the Ashcroft
scoring system (29) using a 100× magni-
fication. Two independent observers
were blinded to the treatment group, and
an average of 10 fields of each lung sec-
tion was selected and scored. The aver-
age Ashcroft score was calculated by av-
eraging the individual field scores.
Statistics
Statistical analyses were conducted
using GraphPad Prism version 5.00
(GraphPad software). Data were ex-
pressed as means ± SEM. Comparisons
between two conditions were analyzed
using two-tailed unpaired t tests when
the data were normally distributed, oth-
erwise Mann-Whitney analysis was per-
formed. P values of less than 0.05 were
considered significant.
All supplementary materials are available
online at www.molmed.org.
RESULTS
PAR-2 Deficiency Attenuates
Bleomycin-Induced Pulmonary
Fibrosis
We previously showed that PAR-2 de-
ficiency limits bleomycin-induced pul-
monary fibrosis when we analyzed mice
14 d after bleomycin instillation (19,30).
To determine whether PAR-2 indeed
drives the progression of pulmonary fi-
brosis or whether its absence would
merely delay the onset of fibrosis, we
compared lungs from wild-type and
PAR-2–deficient mice at d 28 and 48 after
the instillation of bleomycin. As shown
in Figure 1A, bleomycin-induced inflam-
matory and fibrotic processes culminate
in severe pulmonary fibrosis at d 28 in
wild-type mice. In contrast, lung tissue
sections from PAR-2–deficient mice at
d 28 showed significantly reduced inter-
stitial fibrosis, with diminished ECM
deposition and less destruction of alveo-
lar units (Figure 1B). Both wild-type and
PAR-2–deficient mice showed some de-
gree of resolution by d 48 (Figures 1C, D).
Quantification of the bleomycin-induced
histological changes in wild-type and
PAR-2–deficient mice using the Ashcroft
score shows that PAR-2–deficient mice
develop less severe fibrotic lesions at
d 28 than wild-type mice (Figures 1E, F).
These observations are also supported
by hydroxyproline levels indicating that
collagen deposition is significantly re-
duced in PAR-2–deficient lungs at d 28
(Figures 1G, H). Overall, these results
show that PAR-2 deficiency indeed pro-
vides protection against bleomycin-in-
duced pulmonary fibrosis throughout
the fibrotic stage and does not merely
delay disease onset.
P2pal-18S Effectively Inhibits 
PAR-2–Mediated Profibrotic Responses
in Fibroblasts
Next, we determined the specificity of
the observed effects in PAR-2–deficient
mice by assessing whether pharmaco-
logical PAR-2 inhibition by P2pal-18S
would reduce lung fibrosis as well. Be-
fore assessing the in vivo effect of P2pal-
Figure 1. PAR-2 deficiency limits bleomycin-induced pulmonary fibrosis. Representative
H&E-stained lung tissue sections obtained 28 d (A, B) or 48 d (C, D) after bleomycin instilla-
tion in wild-type (WT) (A, C) and PAR-2–/– mice (B, D). Scale bar, 200 μm. (E, F) Quantifica-
tion of pulmonary fibrosis 28 d (E) and 48 d (F) after bleomycin instillation using the
Ashcroft score. Data are expressed as mean ± SEM (n = 8 per group). (G, H) Collagen
content in lung homogenates obtained 28 d (G) or 48 d (H) after bleomycin instillation.
Data are expressed as mean ± SEM (n = 8 per group). *P < 0.05.
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18S, we first determined its specificity
for blocking PAR-2–dependent fibrotic
responses in vitro. Although the speci-
ficity of P2pal-18S has been tested previ-
ously (27), we here used human
platelets (not expressing PAR-2) to con-
firm that P2pal-18S targets only PAR-2
and does not interact with other PARs.
As shown in Figure 2A, PAR-1 activation
by thrombin induced Ca2+ influxes that
peaked within 1 min after stimulation,
whereas pretreatment with 10 μmol/L
P2pal-18S did not interfere with this re-
action. We next assessed whether P2pal-
18S inhibits PAR-2–driven profibrotic
responses in fibroblasts. We show that
trypsin induced fibroblast differentia-
tion, as evident from increased α-SMA
expression and collagen production,
compared with vehicle-treated cells.
Trypsin-induced α-SMA and collagen
expression were clearly downregulated
by the treatment with 10 μmol/L P2pal-
18S (Figure 2B). Bleomycin administra-
tion is known to increase PAR-2 agonist
expression in BALF, which may lead to
fibroblast differentiation or ECM syn-
thesis (19, 31). We therefore next as-
sessed the inhibitory effect of P2pal-18S
against BALF-induced profibrotic effects
on murine fibroblasts. NIH3T3 cells
seeded in BALF of wild-type mice
treated with bleomycin showed in-
creased expression of α-SMA and colla-
gen compared with cells seeded in
BALF derived from saline-treated mice,
whereas preincubation with P2pal-18S
partially decreased this effect (Figure
2C). Finally, we determined whether
Figure 2. P2pal-18S inhibits PAR-2 induced profibrotic responses. (A) Intracellular Ca2+ fluxes in NIH3T3 cells after stimulation with PBS (cir-
cles), 0.1% DMSO (squares) or 1 U/mL thrombin in the absence (down-pointing triangles) or presence (up-pointing triangles) of P2pal-18S
(10 μmol/L). Ca2+ fluxes are expressed as arbitrary units of fluorescent intensity after background correction. (B) Western blot analysis of
α-SMA and collagen expression in NIH3T3 cells stimulated with 10 nmol/L trypsin in the absence or presence of P2pal-18S (10 μmol/L).
P2pal-18S was added 30 min before trypsin stimulation. GAPDH served as loading control. (C) Western blot analysis of α-SMA and colla-
gen expression in NIH3T3 cells 24 h after stimulation with BALF from saline or bleomycin treated WT mice. GAPDH served as a loading
control. (D) Western blot analysis of α-SMA and collagen expression in 3 human control fibroblast cell lines stimulated with 10 nmol/L
trypsin in the absence or presence of P2pal-18S (10 μmol/L). GAPDH served as loading control. (E) Western blot analysis of α-SMA and
collagen expression in 3 IPF fibroblast cell lines stimulated with 10 nmol/L trypsin in the absence or presence of P2pal-18S (10 μmol/L).
GAPDH served as loading control. (F, G) Quantification of α-SMA and collagen expression in control and IPF-derived fibroblasts. (†P < 0.05
and ††P < 0.01 for trypsin stimulation, *P < 0.05 and **P < 0.01 for P2pal-18S effects.)
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P2pal-18S also limits PAR-2–induced fi-
brotic responses on primary human
lung fibroblasts. We stimulated fibrob-
lasts isolated from nonfibrotic controls
and IPF patients with trypsin in the 
absence or presence of P2pal-18S. IPF-
derived fibroblasts exhibited high 
α-SMA and collagen expression persist-
ently (Figures 2D and E showing three
independent fibroblast isolations),
whereas control fibroblasts showed in-
creased α-SMA and collagen expression
only after treatment with trypsin. The
expression of α-SMA and collagen were
reduced by P2pal-18S in both control
and IPF fibroblasts (Figures 2F, G). Im-
portantly, P2pal-18S does not affect un-
stimulated IPF fibroblasts, indicating
that the inhibitory effect is specific to
PAR-2 stimulation (Supplementary Fig-
ure S1). Overall these in vitro data show
that P2pal-18S effectively antagonizes
PAR-2-mediated profibrotic effects in
both murine and human fibroblasts.
P2pal-18S Limits the Development of
Pulmonary Fibrosis in the Bleomycin
Model
After having shown that P2pal-18S 
inhibits PAR-2–induced fibroproliferative
responses in fibroblasts, we set out to ex-
amine whether P2pal-18S would effec-
tively limit fibrosis in the bleomycin
model. To this end, mice were intranasally
instilled with different concentrations of
P2pal-18S (based on previous experi-
ments showing that a similar pepducin-
based inhibitor [P1pal-12; PAR-1 in-
hibitor] was effective at doses of 2.5 and
10 mg/kg but not at a dose of 0.5 mg/kg
[28]), after which the extent and severity
of fibrosis was determined at d 14. As
shown in Figure 3A, bleomycin instilla-
tion resulted in extensive fibrotic foci ac-
companied by increased deposition of
ECM. Both 2.5 mg/kg and 10 mg/kg
P2pal-18S treatment significantly reduced
the severity of regional interstitial fibrosis
(compare Figures 3B and C with 3A).
Quantification of the bleomycin- induced
histopathological changes in the different
groups using the Ashcroft score shows
that P2pal-18S treatment results in less
severe fibrotic lesions (Figure 3D). We
also analyzed total collagen accumulation
in the lung and, as shown in Figure 3E,
bleomycin-induced collagen levels were
attenuated by P2pal-18S treatment, al-
though the 10-mg/kg dose did not reach
statistical significance. We next assessed
TGF-β1 levels in lung homogenates as
TGF-β1 is a key profibrotic cytokine and
its gene and protein expression levels are
known to be increased by bleomycin (32).
As shown in Figure 3F, TGF-β1 levels in-
creased in bleomycin-instilled mice,
whereas the 2.5-mg/kg dose of P2pal-18S
significantly attenuated the TGF-β1 in-
crease by about 50%. The 10-mg/kg dose
of P2pal-18S also reduced TGF-β1 level
but this reduction again did not reach sta-
tistical significance.
Delayed Treatment with P2pal-18S
Effectively Limits Pulmonary Fibrosis
Progression in the Bleomycin Model
After having established that long-
term treatment with P2pal-18S effec-
tively limits bleomycin-induced pul-
monary fibrosis, we assessed whether
preventive and therapeutic modes of ad-
ministration would still be effective. The
bleomycin model is divided in two
phases, namely the inflammatory phase
(up to 7 d after bleomycin challenge)
and the fibrosing phase (after 7 d) (33).
P2pal-18S treatment (2.5 mg/kg) was
consequently started for either 1, 3 (pre-
ventive treatment; concurrent with the
inflammatory phase) or 7 d (therapeutic
treatments; upon the establishment of
lung fibrosis) after bleomycin instilla-
tion and continued once daily till the
end of the experiment. As shown in 
Figures 4A–C, histological analysis of
lung slides from bleomycin-instilled
mice not treated with P2pal-18S again
showed severe fibrotic lesions (about a
five-fold increase compared with lungs
of non–bleomycin-instilled controls).
Treatment with P2pal-18S in the preven-
tive mode strongly inhibited bleomycin-
induced pulmonary fibrosis, as evident
Figure 3. P2pal-18S treatment attenuates bleomycin-induced pulmonary fibrosis. (A–C)
Representative H&E-stained lung tissue sections obtained 14 d after bleomycin instillation
in saline treated mice (A) and mice treated with 2.5 mg/kg (B) or 10 mg/kg P2pal-18S
(C). Scale bar, 200 μm. (D) Quantification of pulmonary fibrosis in control and P2pal-
18S–treated mice using the Ashcroft score. Data are expressed as mean ± SEM (n = 8 per
group). Total collagen content (E) and TGF-β1 levels (F) in lung homogenates of the differ-
ent groups of mice obtained 14 d after saline or bleomycin instillation. Data are ex-
pressed as mean ± SEM (n = 8 per group; *P < 0.05; **P < 0.01).
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from lower Ashcroft scores (Figure 4G)
and reduced collagen accumulation (Fig-
ure 4H). Interestingly, similar findings
were obtained when P2pal-18S was ad-
ministered in the therapeutic mode
(compare Figures 4A and D). Indeed,
P2pal-18S treatment starting on d 7 re-
duced the bleomycin-induced increase
in Ashcroft score (although not statisti-
cally significant) and collagen deposition
(Figures 4G, H).To corroborate the speci-
ficity of P2pal-18S in an in vivo setting,
we analyzed the effect of P2pal-18S
treatment (2.5 mg/kg, starting concur-
rently with bleomycin instillation) in
bleomycin-treated PAR-2–deficient mice.
As shown in Figures 4E and F, PAR-2–
deficient mice developed less fibrosis
than wild-type mice. More importantly,
P2pal-18S treatment did not further re-
duce fibrosis and collagen deposition in
the PAR-2–deficient mice (Figures 4I, J),
suggesting that P2pal-18S limits pul-
monary fibrosis by specifically targeting
PAR-2.
DISCUSSION
IPF is a progressive lung disorders for
which very few therapeutic options are
available (1,3). It is often suggested as an
uncontrolled wound healing response, in
which multiple effectors are tightly in-
volved. PAR-2, as a critical receptor that
orchestrates a diverse range of signaling
pathways, is suggested to play an impor-
tant role in mediating profibrotic effects
in fibroblasts and in preclinical experi-
mental animal models (7,19,20,21,34–36).
Importantly however, the relevance of
PAR-2 in pulmonary fibrosis has recently
been debated, and the actual role of
PAR-2 in pulmonary fibrosis is contro-
versial. In the present study, we aimed to
address the controversy and provide sev-
eral lines of evidence to support the cru-
cial role of PAR-2 in the progression of
pulmonary  fibrosis. Bleomycin-induced
pulmonary fibrosis is stably formed at
around d 14, which is consequently fre-
quently used as an endpoint in the litera-
ture (19,28,37). However, the fibrotic
stage induced by bleomycin peaks at
around 3–4 wks and the reduction in fi-
brosis observed in PAR-2–deficient mice
at d 14 (19,30) may thus indicate only a
delay in the onset of fibrosis instead of
reduced progression. To address this
concern, we increased the follow-up time
and showed that the severity of fibrosis
as well as collagen accumulation are still
significantly reduced in PAR-2–deficient
mice compared with wild-type mice 28 d
after bleomycin instillation. Furthermore,
both wild-type and PAR-2–deficient mice
enter the resolution phase of fibrosis by
d 48, indicating the peak of fibrosis has
passed. By using different endpoints of
the murine bleomycin model, we pro-
vide evidence that PAR-2 deficiency pro-
vides persistent protection throughout
the development of pulmonary fibrosis,
suggesting PAR-2 is indeed an interest-
ing target for therapeutic intervention.
P2pal-18S is a cell-penetrating lipopep-
tide “pepducin” antagonist of PAR-2 that
efficiently blocks PAR-2–dependent in-
flammatory responses in mouse models
(27). We confirm and extend these find-
ings by showing that P2pal-18S effec-
tively blocks PAR-2–driven profibrotic
responses in vitro. Indeed, preincubation
of murine fibroblasts with P2pal-18S
blocks trypsin-induced extracellular
 signal-regulated kinases (ERK) phospho-
rylation, reduces proliferation and mi-
Figure 4. Delayed P2pal-18S treatment effectively attenuates bleomycin-induced pul-
monary fibrosis. (A–F) Representative H&E-stained lung tissue sections obtained 14 d after
bleomycin instillation in wild-type control treated mice (A), wild-type mice treated with
2.5 mg/kg P2pal-18S from d 1 (B), d 3 (C) or d 7 (D) after bleomycin instillation, PAR-2–/–
control treated mice (E) and PAR-2–/– mice treated with 2.5 mg/kg P2pal-18S (F). Scale
bar, 200 μm. (G) Quantification of pulmonary fibrosis in delayed P2pal-18S treated wild-
type mice using the Ashcroft score. (H) Total collagen content in lung homogenates from
the different groups of WT mice obtained 14 d after saline or bleomycin instillation. (I)
Quantification of pulmonary fibrosis in PAR-2–/– mice treated with or without 2.5 mg/kg
P2pal-18S from d 0 after bleomycin instillation using the Ashcroft score. (Note that the
wild-type untreated controls are the same as depicted in panel G, as the experiments
were performed at the same time.) (J) Total collagen content in lung homogenates from
PAR-2–/– mice and PAR-2–/– mice treated with 2.5 mg/kg P2pal-18S obtained 14 d after
bleomycin instillation. The wild-type controls are the same as depicted in panel H. Data
are expressed as mean ± SEM (n = 8 per group; *P < 0.05**P < 0.01).
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gration (30) and diminishes α-SMA and
collagen expression (Figure 2). Moreover,
P2pal-18S significantly inhibits collagen
expression not only in control fibroblasts
but also in IPF- derived human fibrob-
lasts. IPF-derived human fibroblasts ac-
tually exhibit a more differentiated and
fibrotic myofibroblast phenotype, as evi-
dent from elevated basal expression lev-
els of both α-SMA and collagen, which
may explain the reduced responsiveness
to trypsin stimulation compared with
control fibroblasts. As opposed to com-
plete inhibition of trypsin-induced sig-
naling, P2pal-18S only partly blocked
ECM deposition induced by BALF from
bleomycin-treated wild-type mice. This
suggests that BALF partially exerts profi-
brotic effects through PAR-2 activation
but that BALF also contains additional
profibrotic components. Overall, these
data show that P2pal-18S efficiently
blocks PAR-2–dependent fibrotic re-
sponses in vitro. In line with a potential
therapeutic role of PAR-2 in pulmonary
fibrosis, we show for the first time that
P2pal-18S limits bleomycin-induced pul-
monary fibrosis even when administered
at the fibrotic phase. As elegantly re-
viewed, bleomycin administration to ro-
dents results in direct damage to alveolar
epithelial cells, which is followed by an
inflammatory response within the first
week (33). Once alveolar inflammatory
cells are cleared, activated fibroblasts
start to proliferate and to synthesize
ECM, which can already be visualized at
d 7 after bleomycin instillation. Treat-
ments during the first 7 d after
bleomycin administration are conse-
quently considered “preventive,”
whereas treatments starting at d 7 are
considered “therapeutic” (38). After
showing that once daily P2pal-18S treat-
ment (2.5 mg/kg) during the 14 d of the
experiment significantly limited
bleomycin-induced pulmonary fibrosis,
we next showed that administration of
P2pal-18S also effectively decreases the
histological grade of pulmonary fibrosis
and collagen contents in both a preven-
tive (1- and 3-d delayed treatment) and
therapeutic (7-d delayed treatment)
mode. Importantly, the protective effect
afforded by PAR-2 deficiency against
bleomycin-induced pulmonary fibrosis
was nearly identical to that observed in
wild-type mice treated with P2pal-18S.
In PAR-2–deficient mice as well as in
P2pal-18S–treated mice, the severity of
the fibrotic lesions assessed by the
Ashcroft score was decreased by around
1 point. In line with this result, quantita-
tive measurement of collagen deposition
in the lungs was reduced by about 34%
in PAR-2–deficient mice and 29% in
P2pal-18S treated mice. Importantly, the
antifibrotic effect of P2pal-18S was lost in
PAR-2–/– mice, demonstrating that P2pal-
18S is highly specific for PAR-2 in vivo.
This is in accordance with a previous
study (27) showing that P2pal-18S signif-
icantly reduces mouse paw edema and
inflammation in wild-type but not 
PAR-2–deficient mice. Moreover, our in
vitro data show that P2pal-18S does not
interfere with thrombin-induced calcium
fluxes in human platelets. As platelets re-
spond to thrombin through PAR-1
and/or PAR-4 (39), these data indicate
that P2pal-18S does not have cross-
 reactivity with other PARs. 
CONCLUSION
Together, our data indicate that P2pal-
18S provides effective and specific phar-
macologic inhibition of PAR-2 in an ani-
mal model of pulmonary fibrosis and
that inhibition of PAR-2 may thus be a
promising therapeutic strategy for treat-
ing pulmonary fibrosis, although future
clinical studies are needed to confirm
this notion.It is noteworthy that, simi-
larly to what has been observed for tar-
geting PAR-1 in pulmonary fibrosis (28),
P2pal-18S at a dose of 2.5 mg/kg seemed
to be more effective in reducing fibrosis
than a high dose of 10 mg/kg. Although
we do not have a definite explanation for
this finding, it is tempting to speculate
that the phenomenon may be due to the
fact that PAR-2, again similarly to PAR-1,
acts both as a pro- and antiinflammatory
receptor in the respiratory system. In cul-
tured human epithelial cells, activation
of PAR-2 causes release of proinflamma-
tory cytokines such as interleukin (IL)-8
(40). PAR-2 stimulation is also required
for serralysin to activate the critical tran-
scription factors for host inflammatory
responses (41). On the other hand, 
PAR-2 activation enhances LPS-induced
expression of the antiinflammatory cy-
tokines while suppressing gene expres-
sion of proinflammatory cytokines (42)
and PAR-2–toll-like receptor (TLR) sig-
naling integration drives “customized”
inflammatory responses (43). Therefore,
the extent of PAR-2 inhibition may affect
the balance of its pro- and antiinflamma-
tory properties. Alternatively, the slight
differences observed between the 2.5-
and 10-mg doses may simply be attrib-
uted to the variability within the analy-
sis rather than any definable biological
phenomenon, suggesting a dose of 
2.5 mg/kg did already maximally block
PAR-2 signaling. Pharmacological PAR-2
inhibition may not just benefit pul-
monary fibrosis, due to the fact that
PAR-2 influences a large range of patho-
physiological pathways, and indeed
PAR-2 deficiency affords protection from,
among others, renal fibrosis (36), heart
failure (44) and pulmonary hypertension
(45). In line with these data, PAR-2 inhi-
bition reduced, again among others, pul-
monary hypertension, acute biliary pan-
creatitis and osteoarthritis (46,47). It is
thus tempting to speculate that P2pal-
18S may have an impact on a plethora of
other (PAR-2 dependent) disorders, al-
though this tantalizing hypothesis needs
to be addressed experimentally. In sum-
mary, our data endorse the importance of
PAR-2 in mediating profibrotic effects
and identify the PAR-2 antagonist P2pal-
18S as an effective inhibitor of
bleomycin-induced pulmonary fibrosis.
Thus, targeting PAR-2 signaling with
P2pal-18S may offer a novel therapeutic
option for patients with pulmonary 
fibrosis.
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